Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and applied thrombosis/hemostasis 2018-12, Vol.24 (9_suppl), p.340S-349S
Hauptverfasser:	Ramacciotti, Eduardo, Aguiar, Valéria Cristina Resende, Júnior, Valter Castelli, Casella, Ivan Benaducce, Zerati, Antonio Eduardo, Fareed, Jawed
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulants Health risk assessment Humans Latin America Original Practice Guidelines as Topic Pyridines - adverse effects Pyridines - therapeutic use Thiazoles - adverse effects Thiazoles - therapeutic use Thromboembolism Venous Thromboembolism - blood Venous Thromboembolism - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. This practical guide aims to help Latin America clinicians understand edoxaban, its proper indication and its use for the appropriate patients with VTE.
ISSN:	1076-0296 1938-2723
DOI:	10.1177/1076029618812955